Identification of clinical biomarkers for adjuvant chemotherapy in gastric cancer after D2 dissection by pooled analysis of individual patient data from three large randomized clinical trials

Shiro Tanaka; Jia Guan; Kazuhiro Yoshida; Michiya Kobayashi; Shigefumi Yoshino; Kazuaki Tanabe; Takaki Yoshikawa; Takashi Oshima; Yumi Miyashita; Junichi Sakamoto; Akira Tsuburaya

doi:10.4993/acrt.26.43

Shiro Tanaka, Jia Guan, Kazuhiro Yoshida, Michiya Kobayashi, Shigefumi Yoshino, Kazuaki Tanabe, Takaki Yoshikawa, Takashi Oshima, Yumi Miyashita, Junichi Sakamoto, Akira Tsuburaya

著者情報

キーワード: Gastric cancer, Adjuvant chemotherapy, Clinical biomarker, Meta-analysis

ジャーナルフリー

2018 年 26 巻 1 号 p. 43-45

DOI https://doi.org/10.4993/acrt.26.43

詳細

抄録

We aimed to identify prognostic and predictive markers among clinicopathological factors for efficacy of adjuvant chemotherapy in gastric cancer by pooled analysis from 3,521 patients on three large randomized trials: ACTS-GC, CLASSIC, and SAMIT. The primary endpoint was relapse-free survival, and the secondary endpoints were overall survival. The integrity of individual patient data was verified. Significant prognostic markers in surgery alone groups of ACTS-GC and CLASSIC were lower body mass index and advanced stage of disease.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）